What’s the “encorafenib patent CP” / “CPME” referring to?
“CP” and “CPME” are not standard, widely recognized patent acronyms in the same way “US patent” or “EP patent” are. Without the exact full phrase you saw (for example, “CPME,” “CP” plus a number, or the country/agency name next to it), it’s not possible to identify which specific patent document or exclusivity record you mean.
Most people searching this term are usually trying to find one of two things:
- The patent list for encorafenib itself (the active ingredient), or
- The status of regulatory exclusivities/covered periods tied to marketing authorization (which can be confused with patents because they can be listed together in databases).
If you paste the exact wording you saw (and the country or regulator/jurisdiction), I can map it to the specific item.
Which encorafenib products are typically covered by patents/exclusivity?
Encorafenib is sold as part of combination regimens, most commonly with:
- Binimetinib (Braftovi is the brand name in the EU/US; encorafenib + binimetinib)
- In some markets/indications, it’s also associated with other combination contexts, depending on the approved labeling.
Patents can cover different layers: the drug substance (encorafenib), formulations, manufacturing processes, and specific therapeutic use(s).
How to check the right encorafenib patent record (the practical way)
Patent and exclusivity records depend heavily on jurisdiction. To find the one you need, you typically:
1. Identify the jurisdiction (EU/UK/US, etc.).
2. Confirm the product/marketing authorization the record is tied to (brand name and combination partner).
3. Look for the “event” type:
- Patent numbers (publication/grant),
- Supplementary Protection Certificate (SPC) (EU/UK),
- data exclusivity / marketing exclusivity terms in that jurisdiction.
4. Use the marketing authorization holder and product name as the join key, because some databases list only “by product,” not by the active ingredient alone.
Key “timelines” that people usually mean when searching encorafenib patent status
People often want to know when another company can compete (generics/biosimilars or similar small-molecule competition). That depends on multiple overlapping clocks:
- Patent expiration (for the relevant claims),
- Any SPC extension (EU/UK),
- Regulatory data exclusivity and marketing exclusivity (if applicable),
- Any later-life patents for formulations or methods of use (which can delay certain challenges, even after some earlier patents expire).
If you want, I can pinpoint the exact “CPME”/“CP” item—what I need from you
Please provide any of the following from the page/record where you saw “patent cpme”:
- The full text (copy/paste),
- The country/jurisdiction (e.g., EP, UK, US, “EMA,” “MHRA,” etc.),
- The product name (e.g., Braftovi) and combination partner (binimetinib?),
- Any number next to “CPME” or “CP” (even partial).
With that, I can tell you what the referenced encorafenib patent or exclusivity period is and how it affects competition timing.
Sources
No sources were provided in your message, and I don’t have enough detail about “CPME/CP” to cite an authoritative record without risking a wrong match.